PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2011

Tumor necrosis factor-alpha (TNF-alpha) is a therapeutic target for impaired cutaneous wound healing.

Mouse / Wound

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 22151742 ↗2011Reported benefit

Tumor necrosis factor-alpha (TNF-alpha) is a therapeutic target for impaired cutaneous wound healing.

MouseWoundSecretory leukocyte protease inhibitor (SLPI) null mice and wild-type littermates; background strain not statedMalen = Murine group sizes not stated (each mouse carried 4 wounds)…Subcutaneous injection into the area to be incised (described as topical or local application)100 microlitres containing 1 to 10 micrograms of anti-TNF-a…Immediately prior to wounding (day 0)

Model: Four equidistant 1 cm full-thickness dorsal incisional wounds through skin and panniculus carnosus healing by secondary intention in SLPI-null mice with severely impaired healing; human 4 mm punch biopsies and chronic venous ulcers studied in parallel

A single 10 microgram application of anti-TNF-alpha at wounding significantly accelerated healing and reduced wound area in SLPI-null mice (p=0.05 at day 3), with reduced MMP9 activity, less inflammatory infiltrate, reduced NF-kappaB binding and increased collagen. Wild-type wounds healed faster bu…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.